Skip to content
10-K

Annual Report

CENTESSA PHARMACEUTICALS PLC CNTA

0001847903-26-000025

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 17, 2026 154.57M sh
Shares Diluted FY 2025 · Dec 31, 2025 135.72M sh
Shares Diluted FY 2025 · Dec 31, 2024 114.47M sh
Capex FY 2025 · Dec 31, 2025 $371K
Capex FY 2025 · Dec 31, 2024 $34K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$193.82M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$142.06M
Long Term Debt FY 2025 · Dec 31, 2025 $110.1M
Long Term Debt FY 2025 · Dec 31, 2024 $108.94M
Short Term Investments FY 2025 · Dec 31, 2025 $233.28M
Short Term Investments FY 2025 · Dec 31, 2024 $98.96M
Cash And Equivalents FY 2025 · Dec 31, 2025 $61.3M
Cash And Equivalents FY 2025 · Dec 31, 2024 $383.22M
Stockholders Equity FY 2025 · Dec 31, 2025 $526.86M
Stockholders Equity FY 2025 · Dec 31, 2024 $401.55M
Stockholders Equity FY 2025 · Dec 31, 2023 $236.24M
Current Liabilities FY 2025 · Dec 31, 2025 $42.94M
Current Liabilities FY 2025 · Dec 31, 2024 $58M
Total Liabilities FY 2025 · Dec 31, 2025 $160.63M
Total Liabilities FY 2025 · Dec 31, 2024 $175.25M
Current Assets FY 2025 · Dec 31, 2025 $367.88M
Current Assets FY 2025 · Dec 31, 2024 $536.41M
Total Assets FY 2025 · Dec 31, 2025 $687.5M
Total Assets FY 2025 · Dec 31, 2024 $576.8M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.46
Eps Diluted FY 2025 · Dec 31, 2024 −$2.06
Eps Basic FY 2025 · Dec 31, 2025 −$1.46
Eps Basic FY 2025 · Dec 31, 2024 −$2.06
Sga Expense FY 2025 · Dec 31, 2025 $50.47M
Sga Expense FY 2025 · Dec 31, 2024 $50.81M
Net Income FY 2025 · Dec 31, 2025 −$197.53M
Net Income FY 2025 · Dec 31, 2024 −$235.76M
Operating Income FY 2025 · Dec 31, 2025 −$207.69M
Operating Income FY 2025 · Dec 31, 2024 −$201.06M
Revenue FY 2025 · Dec 31, 2025 $15M
Revenue FY 2025 · Dec 31, 2024 $0